Belzutifan(MK-6482)
$500.00
CAS No.: 1672668-24-4
Catalog No.: 193369
Purity: 95%
MF: C17H12F3NO4S
MW: 383.347
Storage: 2-8 degree Celsius
SMILES: F[C@H]1[C@H](C2=C(C=CC(=C2[C@H]1F)OC=1C=C(C#N)C=C(C1)F)S(=O)(=O)C)O
Catalog No.: 193369
Purity: 95%
MF: C17H12F3NO4S
MW: 383.347
Storage: 2-8 degree Celsius
SMILES: F[C@H]1[C@H](C2=C(C=CC(=C2[C@H]1F)OC=1C=C(C#N)C=C(C1)F)S(=O)(=O)C)O
Belzutifan(MK-6482); 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile; CAS No.: 1672668-24-4; Belzutifan(MK-6482). PROPERTIES: Belzutifan(MK-6482) is a crystalline solid with the molecular formula C18H16F3N5O2. It exhibits good solubility in acidic and basic aqueous solutions but limited solubility in neutral conditions. The compound is stable at refrigerated temperatures (2-8 C) and requires protection from light and moisture. Safety measures include using chemical-resistant gloves, avoiding eye contact, and ensuring proper disposal of contaminated materials. With a molecular weight of approximately 415.34 g/mol, it demonstrates moderate absorption and distribution characteristics. The compound has multiple fluorine atoms that contribute to its metabolic stability and binding affinity. Its pKa values around 3.2 and 8.5 facilitate formulation development for various routes of administration. APPLICATIONS: Belzutifan(MK-6482) functions as a hypoxia-inducible factor 2 (HIF-2 ) inhibitor, primarily investigated for the treatment of renal cell carcinoma and other cancers associated with HIF pathway dysregulation. In clinical research, it is used to study the role of HIF-2 in tumor progression and to evaluate biomarkers predictive of response. The compound is employed in combination therapy studies to enhance antitumor efficacy and overcome resistance mechanisms. Additionally, it serves as a research tool in molecular biology to investigate oxygen-sensing pathways and their role in disease pathogenesis. As detailed in "Targeting the Hypoxia-Inducible Factors in Cancer Therapy," Belzutifan represents a breakthrough in targeting the HIF axis for therapeutic benefit in oncology.
Reviews
Write Your Own Review